硼替佐米为主的化疗对多发性骨髓瘤患者血清胱抑素C的影响

Effect of Bortezomib on serum cystatin-C in multiple myeloma

目的探讨血清胱抑素C(Cys-C)能否作为监测肿瘤负荷的潜在指标。方法选择20例多发性骨髓瘤(multi-ple myeloma,MM)患者,给予以硼替佐米(万珂)为主的化疗4个疗程,测定治疗前后血清Cys-C、β2-微球蛋白(β2-MG)的变化,并与收集20例健康体检者对照。结果 MM患者血清Cys-C和β2-MG较对照组升高(P<0.05),经以硼替佐米为主的化疗治疗后,血清Cys-C和β2-MG均下降(P<0.05),复发患者较初发者减少更明显。结论以硼替佐米为主的化疗可明显降低MM患者血清Cys-C、β2-MG水平,Cys-C可以作为肿瘤负荷监测的潜在指标。

Objective The aim of this study was to assess the effect of Bortezomib on serum cystatin-C（Cys-C）in multiple myeloma and whether Cys-C can monitor tumor load.Methods We measured serum Cys-C and β2-microglobulin in multiple myeloma patients and 20 healthy controls pre-and post-Bortezomib therapy.Results Multiple myeloma patients had higher Cys-C and β2-microglobulin levels compared with healthy controls（P0.05）.Treatment with Bortezomib produced a significant reduction of cystatin-C and β2-microglobulin,mainly in relapsed patients（P0.05）.Conclusion Treatment with Bortezomib can significantly reduce the Cys-C levels,which can be regarded as the potential indicator to monitor tumor load,and β2-microglobulin levels of multiple myeloma patients.